Phone 204.453.1408 Fax 204.453.1546 info@miraculins.com



Miraculins Announces Grant of Options

WINNIPEG, Manitoba – August 1, 2014 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that it has granted an aggregate of 1,068,500 stock options at an exercise price of \$0.22 per common share, to certain directors, officers, employees, consultants and management company employees of the Company. The options are set to expire five years from the date of grant and are subject to the approval of the TSX Venture Exchange and the terms of Miraculins' stock option plan.

For more information, please contact:

▼miraculins

Christopher J. Moreau President & CEO Miraculins Inc. Ph: 204-477-7599

Fax: 204-453-1596

info@miraculins.com www.miraculins.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.